Download PDF
Thorac Cardiovasc Surg 2023; 71(03): 206-213
DOI: 10.1055/s-0042-1743433
Original Thoracic

Survival Analysis of Surgically Resected ypN2 Lung Cancer after Neoadjuvant Therapy

Özgür İşgörücü 
1   Department of Thoracic Surgery, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey
,
Necati Citak
2   Department of Thoracic Surgery, Dr. Suat Seren Chest Diseases Training and Research Hospital, Izmir, Turkey
› Author Affiliations
› Further Information
    Permissions and Reprints All articles of this category

Abstract

Introduction Surgery is widely accepted today when downstaging of mediastinal lymph nodes after neoadjuvant therapy is achieved. However, the role of surgery in patients with persistent N2 disease is still controversial. This study aims to detail the diagnostic problems, prognostic features, and long-term survival of the persistent N2 non-small cell lung cancer patient group.

Patients and Methods One-hundred fifty patients who received neoadjuvant therapy and subsequently underwent resection, in-between 2003 and 2015, were retrospectively analyzed. In this study, “persistent N2” group refers to patients who received neoadjuvant therapy for clinically or histologically proven N2, who underwent a surgery after having been classified as “downstaged” at restaging, but in whom ypN2 lesions were subsequently confirmed on the operative specimens. Patients with multistation N2 were included in the study. There were 119 patients who met the criteria, whereas persistent ypN2 was detected in 28.5% (n = 34) of all patients.

Results Overall 5-year survival rate was 47.2%, while it was 23.4% for patients with persistent N2. Factors that adversely affected survival were to have nonsquamous cell histological type (p = 0.006), high ypT stage (p = 0.001), persistent N2 (p = 0.02), and recurrence during follow-up (p < 0.001). A trend toward a shorter survival was observed when the ypN2 zone was subcarinal versus other zones, but did not reach statistical significance (p = 0.08). In addition, a trend toward a shorter survival of patients with multiple N2 involvement (p = 0.412) was observed.

Conclusion In the persistent N2 group, when multiple involvement or subcarinal involvement was excluded, relatively good survival was detected.

Keywords

surgery - chemotherapy - lung cancer - diagnosis


Publication History

Received: 15 August 2021

Accepted: 18 January 2022

Article published online:
02 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Johnson DH, Rusch VW, Turrisi AT. Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007; 99 (06) 415-418
    CrossrefPubMedGoogle Scholar
  • 2 Van Schil PE, Berzenji L, Yogeswaran SK, Hendriks JM, Lauwers P. Surgical management of stage IIIA non-small cell lung cancer. Front Oncol 2017; 7: 249
    CrossrefPubMedGoogle Scholar
  • 3 Van Schil PE, Yogeswaran K, Hendriks JM, Lauwers P, Faivre-Finn C. Advances in the use of surgery and multimodality treatment for N2 non-small cell lung cancer. Expert Rev Anticancer Ther 2017; 17 (06) 555-561
    CrossrefPubMedGoogle Scholar
  • 4 Chiappetta M, Leuzzi G, Sperduti I. et al. Mediastinal up-staging during surgery in non-small-cell lung cancer: which mediastinal lymph node metastasis patterns better predict the outcome? A multicenter analysis. Clin Lung Cancer 2020; 21 (05) 464-471.e1
    CrossrefPubMedGoogle Scholar
  • 5 Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines. Chest 2013; 143 (05) 7-37
    PubMedGoogle Scholar
  • 6 Betticher DC, Hsu Schmitz SF, Tötsch M. et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003; 21 (09) 1752-1759
    CrossrefPubMedGoogle Scholar
  • 7 Brunelli A, Rocco G, Szanto Z, Thomas P, Falcoz PE. Morbidity and mortality of lobectomy or pneumonectomy after neoadjuvant treatment: an analysis from the ESTS database. Eur J Cardiothorac Surg 2020; 57 (04) 740-746
    CrossrefPubMedGoogle Scholar
  • 8 Lorent N, De Leyn P, Lievens Y. et al; Leuven Lung Cancer Group. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 2004; 15 (11) 1645-1653
    CrossrefPubMedGoogle Scholar
  • 9 Port JL, Korst RJ, Lee PC. et al. Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg 2005; 79 (05) 1686-1690
    CrossrefPubMedGoogle Scholar
  • 10 İşgörücü Ö, Citak N. Survival analysis of pathological complete response of locally advanced lung cancer after neoadjuvant treatment. Gen Thorac Cardiovasc Surg 2021; 69 (07) 1086-1095
    CrossrefPubMedGoogle Scholar
  • 11 Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e78S-e92S
    CrossrefPubMedGoogle Scholar
  • 12 Asamura H, Chansky K, Crowley J. et al; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol 2015; 10 (12) 1675-1684
    CrossrefPubMedGoogle Scholar
  • 13 Schwartz LH, Litière S, de Vries E. et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 2016; 62: 132-137
    CrossrefPubMedGoogle Scholar
  • 14 Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 2008; 26 (07) 1128-1134
    CrossrefPubMedGoogle Scholar
  • 15 Betticher DC, Hsu Schmitz SF, Tötsch M. et al; Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006; 94 (08) 1099-1106
    CrossrefPubMedGoogle Scholar
  • 16 Albain KS, Swann RS, Rusch VW. et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374 (9687): 379-386
    CrossrefPubMedGoogle Scholar
  • 17 van Meerbeeck JP, Kramer GW, Van Schil PE. et al; European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007; 99 (06) 442-450
    CrossrefPubMedGoogle Scholar
  • 18 Thomas M, Rübe C, Hoffknecht P. et al; German Lung Cancer Cooperative Group. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008; 9 (07) 636-648
    CrossrefPubMedGoogle Scholar
  • 19 Martin J, Ginsberg RJ, Venkatraman ES. et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 2002; 20 (08) 1989-1995
    CrossrefPubMedGoogle Scholar
  • 20 Okuda M, Go T, Yokomise H. Risk factor of bronchopleural fistula after general thoracic surgery: review article. Gen Thorac Cardiovasc Surg 2017; 65 (12) 679-685
    CrossrefPubMedGoogle Scholar
  • 21 Mansour Z, Kochetkova EA, Santelmo N. et al. Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy. Ann Thorac Surg 2008; 86 (01) 228-233
    CrossrefPubMedGoogle Scholar
  • 22 Dickhoff C, Dahele M, Paul MA. et al. Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer. Lung Cancer 2016; 94: 108-113
    CrossrefPubMedGoogle Scholar
  • 23 Bueno R, Richards WG, Swanson SJ. et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000; 70 (06) 1826-1831
    CrossrefPubMedGoogle Scholar
  • 24 Kamigaichi A, Tsutani Y, Mimae T. et al. Prediction of unexpected N2 disease associated with clinical T1-2N0-1M0 non-small-cell lung cancer. Clin Lung Cancer 2021; 22 (02) 120-126.e3
    CrossrefPubMedGoogle Scholar
  • 25 Keshava HB, Tan KS, Dycoco J. et al. How effective is neoadjuvant therapy followed by surgery for pathologic single-station N2 non-small cell lung cancer?. Semin Thorac Cardiovasc Surg 2021; 33 (01) 206-216
    CrossrefPubMedGoogle Scholar
  • 26 Montemuiño S, Dios NR, Martín M. et al. High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Rep Pract Oncol Radiother 2020; 25 (03) 447-455
    CrossrefPubMedGoogle Scholar
  • 27 Rusch VW, Crowley J, Giroux DJ. et al; International Staging Committee, Cancer Research and Biostatistics, Observers to the Committee, Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2 (07) 603-612
    CrossrefPubMedGoogle Scholar
  • 28 Detterbeck F. What to do with “Surprise” N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol 2008; 3 (03) 289-302
    CrossrefPubMedGoogle Scholar
  • 29 Ichinose Y, Kato H, Koike T. et al; Japanese Clinical Oncology Group. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg 2001; 122 (04) 803-808
    CrossrefPubMedGoogle Scholar
  • 30 Goldstraw P. Selection of patients for surgery after induction chemotherapy for N2 non-small-cell lung cancer. J Clin Oncol 2006; 24 (21) 3317-3318
    CrossrefPubMedGoogle Scholar
  • 31 White AA, Lee DN, Mazzola E. et al. Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer. J Surg Oncol 2021; 123 (02) 579-586
    CrossrefPubMedGoogle Scholar
  • 32 Cafarotti S, Cesario A, Cusumano G, Granone P. Single station N2 NSCLC: a brief reflection on possible overdoing. Ann Thorac Surg 2009; 88 (06) 2069-2070 , author reply 2070
    CrossrefPubMedGoogle Scholar
  • 33 Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47 (01) 207-214
    CrossrefPubMedGoogle Scholar
  • 34 Martini N, Kris MG, Flehinger BJ. et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55 (06) 1365-1373 , discussion 1373–1374
    CrossrefPubMedGoogle Scholar
  • 35 Elias AD, Skarin AT, Gonin R. et al. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results. Am J Clin Oncol 1994; 17 (01) 26-36
    CrossrefPubMedGoogle Scholar
  • 36 Vansteenkiste JF, De Leyn PR, Deneffe GJ. et al; Leuven Lung Cancer Group. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg 1997; 63 (05) 1441-1450
    CrossrefPubMedGoogle Scholar
  • 37 Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg 2008; 86 (03) 912-920 , discussion 912–920
    CrossrefPubMedGoogle Scholar
  • 38 Decaluwé H, De Leyn P, Vansteenkiste J. et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg 2009; 36 (03) 433-439
    CrossrefPubMedGoogle Scholar